Dr. John Cush RheumNow
1 month 1 week ago
Rheum Survey >> What therapy do you most commonly use to treat Sjogrens disease? Answer here: https://t.co/XJEsqoSlbn
Dr. John Cush RheumNow
1 month 1 week ago
Efgartigimod Efficacy in Idiopathic Inflammatory Myopathy
Today Argenx announced the results of their Phase 3 "ALKIVIA" study; demonstrating efficacy and safety of subcutaneous efgartigimod for Idiopathic Inflammatory Myopathy (IIM, AKA inflammatory myositis). https://t.co/TYP4KcdLoa
Dr. John Cush RheumNow
1 month 1 week ago
Can Effective Psoriasis Therapy Prevent Psoriatic Arthritis?
A review article assesses and integrates mechanistic, imaging, and clinical evidence to examine whether effective treatment of psoriasis may modify the future risk of psoriatic arthritis (PsA). https://t.co/3gnV3eaKiu
High fever, strange rashes, scary labs often lead to a consideration of Still's disease (AOSD or systemic JIA). Yet the dramatic onset of a systemic disorder may overlap with another, and possibly as rare, systemic disorder that should not be misdiagnosed or mistreated. A current case review by Zhu et al. presents six cases initially diagnosed as systemic JIA, teaching several important lessons.
Dr. John Cush RheumNow
1 month 1 week ago
"Great teachers set it up, and great students find the aha."
- Seth Godin https://t.co/Fc3SPdsYCE
Dr. John Cush RheumNow
1 month 1 week ago
In 2026 Abbvie granted 34 scholarships to students With Inflammatory Diseases. In the last 10 yrs, theyve granted $6 million to >350 students in the US for higher education. These awards up to $20,000 per student renewable up to 4 yrs. https://t.co/DFy5SukB6G https://t.co/9mVkrhL2lo
RA confers a 50–100% excess risk of venous thromboembolism (VTE) compared with the general population, with adjusted hazard/odds ratios ranging from 1.3–2.2 across large cohort studies (Vojinovic, Askling, Antovic; Rheumatology, 2026).
Dr. John Cush RheumNow
1 month 1 week ago
Doubting RS3PE (8.14.2026)
Dr. Jack Cush reviews the news and journal articles this week where RheumNow featured info on cancer, deadly viruses, AI rules, poetry and good moons rising.
https://t.co/gmcrjb5bDu https://t.co/LiLl7XcZQS
Dr. John Cush RheumNow
1 month 1 week ago
Multiple chronic conditions (MCCs; AKA multimorbidity) is highly prevalent in AIRDs; complicates Rx & increases adverse outcomes & all-cause mortality. MMCs 86% in RA, 81.5% in SLE, w/ a notable patterns of cardiopulmonary and mental health disorders https://t.co/AOWCsEodXR https://t.co/NyAR0TUQkE
Dr. John Cush RheumNow
1 month 1 week ago
2026 Medscape report on Nurse practitioners shows nearly half of NPs are burned out, and for 1 in 6, that exhaustion has curdled into something heavier: both burnout and depression. Worse, 63% of NPs don't believe relief is in sight https://t.co/G8N5YgOKyA
Dr. John Cush RheumNow
1 month 1 week ago
SLE & Dermatomyositis rashes maybe classically red or violaceous in Whites,but different in people of color, where erythema often appears brown/violaceous, Gottron papules can be mistaken for "dry skin." This delays dx, especially in anti-MDA5+ RP-ILD, where rash may be the https://t.co/Savx5IOTcG
A current report from the national NHIS survey shows that over half of US adults diagnosed with arthritis reported moderate to severe joint pain.
Shoulder pain affects 16% of adults annually and is the third most common musculoskeletal presentation in primary care. This new review reframes the diagnostic and therapeutic approach, moving away from pathoanatomic labels (rotator cuff tendinopathy, impingement, bursitis) toward the umbrella term subacromial pain, since structural findings on imaging correlate poorly with symptoms and are common in asymptomatic people.
Dr. John Cush RheumNow
1 month 1 week ago
Rheum Survey >> What therapy do you most commonly use to treat Sjogrens disease? Answer here: https://t.co/XJEsqoSlbn
Dr. John Cush RheumNow
1 month 1 week ago
Review of CAR-T 29 trials in systemic sclerosis (SSc): 27/29 target CD19 (other CD20, BCMA), 20/29 autologous. Only 2 RCTs; 1 w/ RTX comparator. Most included CREST. Schetts largest series had 6 dcSSc w/ skin/lung improvements. Need fewer & larger multicenter RCTs https://t.co/Me28HbaFhR

